Blood Reviews
Volume 24, Issue 4 , Pages 171-178 , July 2010

Unprovoked Venous Thromboembolism: Short term or Indefinite Anticoagulation? Balancing Long-Term Risk and Benefit

  • M. Rodger

      Affiliations

    • Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada
    • Ottawa Hospital Research Institute, Ottawa, Ottawa, ON, Canada
    • Corresponding Author InformationCorresponding author. University of Ottawa, Ottawa Hospital, General Campus; 501 Smyth Road, Rm W6116, Box 201, Ottawa, ONT, Canada K1H 8L6. Tel.: 613 737 8899x74641; fax: 613 739 6102.
    • ,
  • M. Carrier

      Affiliations

    • Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada
    • Ottawa Hospital Research Institute, Ottawa, Ottawa, ON, Canada
    • Ottawa Hospital, General Campus, 501 Smyth Rd., Ottawa, ONT, Canada K1H 8L6. Tel.: 613 737 8899x73034; fax: 613 739 6266.
    • ,
  • E. Gandara

      Affiliations

    • Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada
    • Ottawa Hospital Research Institute, Ottawa, Ottawa, ON, Canada
    • Ottawa Hospital, Civic Campus, 1053 Carling Ave., Ottawa, ONT, Canada K1Y 4E9. Tel.: 613 798 5555x12692; fax: 613 761 5044.
    • ,
  • G. Le Gal

      Affiliations

    • Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest, France
    • Centre Hospitalier Universitaire de Brest, 29609 Brest Cedex, Brest, France. Tel.: 011 33 2 98 34 73 51; fax: 011 02 98 34 79 44.

References 

  1. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756–764
  2. Ageno W, Prandoni P, Romualdi E, Ghirarduzzi A, Dentali F, Pesavento R, et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost. 2006;4:1914–1918
  3. Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis. 2006;21:23–29
  4. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107:I-4–I-8
  5. Prins MH, Marchiori A. Risk of recurrent venous thomboembolism—expanding the frontier. Thromb Haemost. 2002;87:1–3
  6. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585–593
  7. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester study. Arch Intern Med. 1991;151:933–938
  8. Kahn SR. The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis. J Thromb Thrombolysis. 2006;21:41–48
  9. Schulman S, Lindmarker P, Holmstrom M, Larfars G, Carlsson A, Nicol P, et al. Post-thrombotic syndrome, recurrence, and death 10years after the first episode of venous thromboembolism treated with warfarin for 6weeks or 6months. J Thromb Haemost. 2006;4:734–742
  10. Kearon C, Ginsberg JS, Anderson DR, Kovacs MJ, Wells PS, Julian JA, et al. A Comparison of 1month with 3months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost. 2004;2:743–749
  11. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight Heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153
  12. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilia risk factors: prospective cohort study. Lancet. 2003;362:523–526
  13. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160:761–768
  14. Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1–7
  15. Research Committee of the British Thoracic Society . Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet. 1992;340(8824):873–876
  16. Segal JB, Streiff MB, Hoffman LV, Thornton K, Bass EB. Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med. 2007;146:211–222
  17. Baglin T. Unprovoked deep vein thrombosis should be treated with long-term anticoagulation — no. J Thromb Haemost. 2007;5:2336–2339
  18. Kearon C. Indefinite anticoagulation after a first episode of unprovoked venous thromboembolism: yes. J Thromb Haemost. 2007;5:2330–2335
  19. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425–1434
  20. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901–907
  21. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med. 2001;345:165–169
  22. Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003;139:19–25
  23. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119:176S–193S
  24. Kearon C, Kahn SR, Agnelli G, Goldhaber SZ, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. (8th edition). Chest. 2008;133(Supplement):454–545
  25. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199–205
  26. Jimenez D, Diaz G, Marin E, Vidal R, Sueiro A, Yusen RD. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism. Thromb Haemost. 2006;95:562–566
  27. Prandoni P, Hutten BA, van Dongen CJ, Pesavento R, Prins MH. Quality of oral anticoagulant treatment and risk of subsequent recurrent thromboembolism in patients with deep vein thrombosis. J Thromb Haemost. 2007;5:1555
  28. Ost D, Tepper J, Mihara H, Lander O, Heinzer R, Fein A. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA. 2005;294:706–715
  29. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, et al. Comparison of 3 and 6months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001;103:2453–2460
  30. Pinede L, Duhaut P, Cucherat M, Ninet J, Pasquier J, Boissel JP. Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials. J Intern Med. 2000;247:553–562
  31. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells PS, Julian JA, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631–639
  32. Schulman S, Wahlander K, Lundstrom T, Billing Classon S, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349:1713–1721
  33. Douketis JD, Kearon C, Bates SM, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279:458–462
  34. Linkins L-A, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. A meta-analysis. Ann Intern Med. 2003;139:893–900
  35. Carrier M, Le Gal G, Wells PS, Rodger MA. Abstract: case fatality rate of recurrent venous thromboembolism and major bleeding during and following anticoagulation therapy. J Thromb Haemost. 2009;7(s2):1031;(Ref Type: Abstract)
  36. Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules. Applications and methodological standards. N Engl J Med. 1985;313:793–799
  37. Laupacis A, Sekar N, Stiell IG. Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA. 1997;277:488–494
  38. Reilly BM, Evans AT. Translating clinical research into clinical practice: impact of using prediction rules to make decisions. Ann Intern Med. 2006;144:201–209
  39. Stiell IG, Wells GA. Methodologic standards for the development of clinical decision rules in emergency medicine. Ann Emerg Med. 1999;33(4):437–447
  40. McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet. 2006;368:371–378
  41. Stain M, Schonauer V, Minar E, Bialonczyk C, Hirschl M, Weltermann A, et al. The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. J Thromb Haemost. 2005;3(12):2671–2676
  42. Eichinger S, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Schneider B, et al. D-Dimer levels and risk of recurrent venous thromboembolism. JAMA. 2003;290:1071–1074
  43. Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolism recurrence: high negative predictive value of D-Dimer performed after oral anticoagulation is stopped. Thromb Haemost. 2002;87:7–12
  44. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, et al. D-Dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355:1780–1789
  45. Cosmi B, Legnani C, Cini M, Guazzaloca G, Palareti G. The role of D-Dimer and residual venous obstruction in recurrence of venous thromboembolism after anticoagulation withdrawal in cancer patients. Haematologica. 2005;90:713–715
  46. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, et al. High plasma levels of Factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343(7):457–462
  47. Kraaijenhagen RA, Anker PS, Koopman MMW, Reitsma PH, Prins MH, van den Ende A, et al. High plasma concentration of Factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. 2000;83(1):5–9
  48. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia. A systematic review. Arch Intern Med. 2006;166:729–736
  49. Rodger MA, Kovacs MJ, Kahn SR, Wells PS, Anderson DR, Le Gal G, et al. Abstract: extended follow-up of the multi-center multi-National prospective cohort study that derived the “Men Continue and HERDOO2” Clinical Decision rule which identifies low risk patients who may be able to discontinue oral anticoagulants (OAC) 5–7months after treatment for unprovoked venous thromboembolism (VTE). Blood. 2009;114(22):187;(Ref Type: Abstract)
  50. Piovella F, Crippa L, Barone M, Vigano-D'Angelo S, Serafini S, Galli L, et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica. 2002;87:515–522
  51. Prandoni P, Lensing AW, Prins MH, Bernardi E, Marchiori A, Bagatella P, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002;137:955–960
  52. Siragusa S, Malato A, Anastasio R, Cigna V, Milio G, Amato C, et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood. 2008;112:511–515
  53. Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T, et al. Systematic review: D-Dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med. 2008;149:481–490(W-94)
  54. Palareti G, Legnani C, Cosmi B, Valdre L, Lunghi B, Bernardi F, et al. Predictive value of D-Dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation. 2003;108:313–318
  55. Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179:417–426
  56. Linkins LA, Stretton R, Probyn L, Kearon C. Interobserver agreement on ultrasound measurements of residual vein diameter, thrombus echogenicity and Doppler venous flow in patients with previous venous thrombosis. Thromb Res. 2006;117:241–247
  57. Rodger MA, Kahn SR, Le Gal G, Solymoss S, Chagnon I, Anderson DR, et al. Inter-observer reliability of measures to assess the post-thrombotic syndrome. Thromb Haemost. 2008;100(1):164–166

PII: S0268-960X(10)00024-X

doi: 10.1016/j.blre.2010.06.001

Blood Reviews
Volume 24, Issue 4 , Pages 171-178 , July 2010

Article Tools

* Image Usage & Resolution